HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Raises Price Target to $146
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein maintains a 'Buy' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $140 to $146.
August 21, 2023 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' price target has been raised from $140 to $146 by HC Wainwright & Co.
The raised price target indicates the analyst's increased confidence in the company's future performance. This could potentially lead to an increase in the stock's price as investors react to the new price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100